State of Alaska Department of Revenue Grows Position in Masimo Co. (NASDAQ:MASI)

State of Alaska Department of Revenue grew its stake in Masimo Co. (NASDAQ:MASI) by 7.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 5,139 shares of the medical equipment provider’s stock after buying an additional 345 shares during the quarter. State of Alaska Department of Revenue’s holdings in Masimo were worth $685,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of the stock. Farallon Capital Management LLC boosted its position in Masimo by 13.6% in the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after purchasing an additional 177,914 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after purchasing an additional 360,497 shares in the last quarter. Point72 Asset Management L.P. boosted its position in Masimo by 107.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after purchasing an additional 351,523 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Masimo by 45.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock worth $66,201,000 after buying an additional 165,257 shares during the period. Finally, Bamco Inc. NY acquired a new position in shares of Masimo during the 1st quarter worth approximately $50,781,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wells Fargo & Company upped their target price on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research note on Wednesday. BTIG Research upped their target price on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Piper Sandler upped their target price on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday. Finally, Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $152.57.

Masimo Stock Up 10.6 %

NASDAQ MASI opened at $167.63 on Thursday. The business has a fifty day moving average price of $131.74 and a 200 day moving average price of $125.64. Masimo Co. has a one year low of $75.36 and a one year high of $173.90. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.15 and a current ratio of 2.09. The company has a market cap of $8.92 billion, a P/E ratio of 114.03 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.07% and a net margin of 3.94%. The business had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same period last year, the company earned $0.63 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Research analysts anticipate that Masimo Co. will post 3.88 EPS for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.